Molecular targeting agents such as those targeting vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), fibroblast growth factor receptor, and mammalian target of rapamycin have been successfully used in several types of cancers, presenting encouraging results in extending patient survival [6, 7, 10]. This evidence concerns the gene EGFR and cancer.